Dry Eye Disease Pipeline Insight, 2022 – In-depth Insights Into the Latest Clinical, Commercial, and Regulatory Updates | Key Companies – Aldeyra Therapeutics, RegeneRx, Mitotech, TearSolutions

November 21 15:16 2022
Dry Eye Disease Pipeline Insight, 2022 - In-depth Insights Into the Latest Clinical, Commercial, and Regulatory Updates | Key Companies - Aldeyra Therapeutics, RegeneRx, Mitotech, TearSolutions
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Dry Eye Disease therapeutics landscape based on different Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Dry Eye Disease Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Dry Eye Disease Market. 

The Dry Eye Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Dry Eye Disease Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into emerging therapies for treating Dry Eye Disease and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Eye Disease Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dry Eye Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Delveinsight’s Report Covers Around 50+ Products Under Different Phases of Clinical Development Like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage products (Phase I) 

  • Pre-clinical and Discovery stage candidates,

  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Dry Eye Disease Therapeutic Segment:


Dry Eye Disease Therapeutics Landscape

There are approx. 50+ key companies developing therapies for Dry Eye Disease. Currently, RegeneRx Biopharmaceuticals has its Dry Eye Disease drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Dry Eye Disease Therapeutics Market include:

  • TearSolutions

  • HanAll Biopharma

  • Aldeyra Therapeutics

  • RegeneRx Biopharmaceuticals

  • Mitotech

  • Novaliq

  • Oyster Point Pharma

  • Aerie Pharmaceuticals

  • Azura Ophthalmics

  • Stuart Therapeutics

  • Surface Ophthalmics

  • Glaukos Corporation

And many more

Dry Eye Disease Drugs Covered in the Report Include:

  • Reproxalap: Aldeyra Therapeutics

  • Timbetasin: RegeneRx Biopharmaceuticals

  • Visomitin: Mitotech

And many others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:


Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Dry Eye Disease Current Treatment Patterns

4. Dry Eye Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Dry Eye Disease Late Stage Products (Phase-III)

7. Dry Eye Disease Mid-Stage Products (Phase-II)

8. Dry Eye Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dry Eye Disease Discontinued Products

13. Dry Eye Disease Product Profiles

14. Key Companies in the Dry Eye Disease Market

15. Key Products in the Dry Eye Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Dry Eye Disease Unmet Needs

18. Dry Eye Disease Future Perspectives

19. Dry Eye Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Dry Eye Disease Market Insight

“Dry Eye Disease Market Outlook 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dry Eye Disease market size, shares, and trends analysis in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/